当前位置: 首页 >> 检索结果
721. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes.
作者: Anna Lyra.;Lotta Krogius-Kurikka.;Janne Nikkilä.;Erja Malinen.;Kajsa Kajander.;Kyösti Kurikka.;Riitta Korpela.;Airi Palva.
来源: BMC Gastroenterol. 2010年10卷110页
Probiotics can alleviate the symptoms of irritable bowel syndrome (IBS), possibly by stabilizing the intestinal microbiota. Our aim was to determine whether IBS-associated bacterial alterations were reduced during multispecies probiotic intervention consisting of Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99. The intervention has previously been shown to successfully alleviate gastrointestinal symptoms of IBS.
722. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
作者: K Rajender Reddy.;Mitchell L Shiffman.;Maribel Rodriguez-Torres.;Hugo Cheinquer.;Djamal Abdurakhmanov.;Igor Bakulin.;Viacheslav Morozov.;Giovanni Faria Silva.;Natalia Geyvandova.;Carol Stanciu.;Michael Rabbia.;Michael McKenna.;James A Thommes.;Stephen A Harrison.; .
来源: Gastroenterology. 2010年139卷6期1972-83页
Patients infected with hepatitis C virus (HCV) genotype 1, body weight ≥85 kg, and high baseline viral load respond poorly to standard doses of pegylated interferon (peginterferon) and ribavirin. We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin.
723. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
作者: Theodora E M S de Vries-Sluijs.;Jurriën G P Reijnders.;Bettina E Hansen.;Hans L Zaaijer.;Jan M Prins.;Suzan D Pas.;Martin Schutten.;Andy I M Hoepelman.;Clemens Richter.;Jan W Mulder.;Rob A de Man.;Harry L A Janssen.;Marchina E van der Ende.
来源: Gastroenterology. 2010年139卷6期1934-41页
We investigated the long-term efficacy and renal safety of tenofovir disoproxil fumarate (TDF), administered to patients co-infected with human immunodeficiency virus and hepatitis B virus (HBV) as part of an antiretroviral therapy.
724. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
作者: Jeffrey M Johnston.;Caroline B Kurtz.;James E Macdougall.;Bernard J Lavins.;Mark G Currie.;Donald A Fitch.;Chris O'Dea.;Mollie Baird.;Anthony J Lembo.
来源: Gastroenterology. 2010年139卷6期1877-1886.e2页
Linaclotide, a minimally absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-concept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C.
725. Proton pump inhibitor therapy improves symptoms in postnasal drainage.
作者: Michael F Vaezi.;David D Hagaman.;James C Slaughter.;S Bobo Tanner.;James A Duncavage.;Christine T Allocco.;Christy Sparkman.;Lynn E Clement.;Cynthia M Wasden.;Dana Wirth.;Marion Goutte.;Barbara A McCafferty.;Donald C Lanza.
来源: Gastroenterology. 2010年139卷6期1887-1893.e1; quiz e11页
Gastroesophageal reflux is common among patients with postnasal drainage. We investigated whether proton pump inhibitor therapy improved symptoms in patients with postnasal drainage without sinusitis or allergies.
726. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
作者: Mark S Sulkowski.;Mitchell L Shiffman.;Nezam H Afdhal.;K Rajender Reddy.;Jonathan McCone.;William M Lee.;Steven K Herrine.;Stephen A Harrison.;F Fred Poordad.;Kenneth Koury.;Weiping Deng.;Stephanie Noviello.;Lisa D Pedicone.;Clifford A Brass.;Janice K Albrecht.;John G McHutchison.; .
来源: Gastroenterology. 2010年139卷5期1602-11, 1611.e1页
Hepatitis C virus (HCV) treatment is frequently complicated by anemia from ribavirin (RBV)-related hemolysis and peginterferon-alfa (PEG-IFN)-related bone marrow suppression. We investigated the relationships among treatment outcomes, anemia, and their management with RBV dose reduction and/or erythropoiesis-stimulating agents (ESAs).
727. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.
作者: Archana S Rao.;Banny S Wong.;Michael Camilleri.;Suwebatu T Odunsi-Shiyanbade.;Sanna McKinzie.;Michael Ryks.;Duane Burton.;Paula Carlson.;Jesse Lamsam.;Ravinder Singh.;Alan R Zinsmeister.
来源: Gastroenterology. 2010年139卷5期1549-58, 1558.e1页
Sodium chenodeoxycholate (CDC) accelerates colonic transit in health. Our aim was to examine pharmacodynamics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).
728. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis.
作者: Alex Straumann.;Sebastien Conus.;Lukas Degen.;Stephanie Felder.;Mirjam Kummer.;Hansjürg Engel.;Christian Bussmann.;Christoph Beglinger.;Alain Schoepfer.;Hans-Uwe Simon.
来源: Gastroenterology. 2010年139卷5期1526-37, 1537.e1页
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus characterized by dense tissue eosinophilia; it is refractory to proton pump inhibitor therapy. EoE affects all age groups but most frequently individuals between 20 and 50 years of age. Topical corticosteroids are effective in pediatric patients with EoE, but no controlled studies of corticosteroids have been reported in adult patients.
729. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
作者: Mark G Swain.;Ming-Yang Lai.;Mitchell L Shiffman.;W Graham E Cooksley.;Stefan Zeuzem.;Douglas T Dieterich.;Armand Abergel.;Mário G Pessôa.;Amy Lin.;Andreas Tietz.;Edward V Connell.;Moisés Diago.
来源: Gastroenterology. 2010年139卷5期1593-601页
A sustained virologic response (SVR) to therapy for hepatitis C virus (HCV) infection is defined as the inability to detect HCV RNA 24 weeks after completion of treatment. Although small studies have reported that the SVR is durable and lasts for long periods, it has not been conclusively shown.
730. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
作者: Alessandra Mangia.;Alexander J Thompson.;Rosanna Santoro.;Valeria Piazzolla.;Hans L Tillmann.;Keyur Patel.;Kevin V Shianna.;Leonardo Mottola.;Daniela Petruzzellis.;Donato Bacca.;Vito Carretta.;Nicola Minerva.;David B Goldstein.;John G McHutchison.
来源: Gastroenterology. 2010年139卷3期821-7, 827.e1页
Polymorphisms in the region of the interleukin (IL)-28B gene on chromosome 19 have been associated with peginterferon-alfa-induced clearance of genotype 1 hepatitis C virus (HCV); there are no data for patients with genotype 2 or 3 HCV. We evaluated the effects of IL-28B polymorphisms on response to treatment with peginterferon and ribavirin in a well-characterized cohort of genotype 2/3 patients.
731. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial.
作者: Paul Kelly.;Tamara Shawa.;Stayner Mwanamakondo.;Rose Soko.;Geoff Smith.;G Robin Barclay.;Ian R Sanderson.
来源: BMC Gastroenterol. 2010年10卷72页
Although micronutrient supplementation can reduce morbidity and mortality due to diarrhoea, nutritional influences on intestinal host defence are poorly understood. We tested the hypothesis that micronutrient supplementation can enhance barrier function of the gut.
732. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus.
作者: Wouter L Curvers.;Lorenza Alvarez Herrero.;Michael B Wallace.;Louis-Michel Wong Kee Song.;Krish Ragunath.;Herbert C Wolfsen.;Ganapathy A Prasad.;Kenneth K Wang.;Venkataraman Subramanian.;Bas L A M Weusten.;Fiebo J Ten Kate.;Jacques J G H M Bergman.
来源: Gastroenterology. 2010年139卷4期1106-14页
Endoscopic tri-modal imaging (ETMI) incorporates high-resolution endoscopy (HRE), autofluorescence imaging (AFI), and narrow band imaging (NBI). A recent uncontrolled study found that ETMI improved the detection of high-grade dysplasia (HGD) and early carcinoma (Ca) in Barrett's esophagus (BE). The aim was to compare ETMI with standard video endoscopy (SVE) for the detection of HGD/Ca with the use of a randomized cross-over design.
733. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.
作者: Michael P Manns.;Marek Woynarowski.;Wolfgang Kreisel.;Yoav Lurie.;Christian Rust.;Elimelech Zuckerman.;Matthias J Bahr.;Rainer Günther.;Rolf W Hultcrantz.;Ulrich Spengler.;Ansgar W Lohse.;Ferenc Szalay.;Martti Färkkilä.;Markus Pröls.;Christian P Strassburg.; .
来源: Gastroenterology. 2010年139卷4期1198-206页
Autoimmune hepatitis (AIH) is a chronic liver disease associated with cirrhosis and liver failure. Corticosteroid therapy induces long-term remission but has many side effects. We compared the effects of budesonide (a steroid that is rapidly metabolized, with low systemic exposure) and prednisone, both in combination with azathioprine.
734. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
作者: Thomas Berg.;Patrick Marcellin.;Fabien Zoulim.;Bernd Moller.;Huy Trinh.;Sing Chan.;Emilio Suarez.;Fabien Lavocat.;Andrea Snow-Lampart.;David Frederick.;Jeff Sorbel.;Katyna Borroto-Esoda.;David Oldach.;Franck Rousseau.
来源: Gastroenterology. 2010年139卷4期1207-17页
We compared treatments for patients with chronic hepatitis B virus (HBV) infection who had an incomplete response to adefovir dipivoxil (ADV). We evaluated a combination of fixed-dose emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) from the start (early combination) versus TDF as monotherapy.
735. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
作者: David R Nelson.;Yves Benhamou.;Wan-Long Chuang.;Eric J Lawitz.;Maribel Rodriguez-Torres.;Robert Flisiak.;Jens W F Rasenack.;Wiesław Kryczka.;Chuan-Mo Lee.;Vincent G Bain.;Stephen Pianko.;Keyur Patel.;Patrick W Cronin.;Erik Pulkstenis.;G Mani Subramanian.;John G McHutchison.; .
来源: Gastroenterology. 2010年139卷4期1267-76页
A phase 3 active-controlled study was conducted to assess the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chronic hepatitis C virus (HCV) genotype 2/3.
736. Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease.
作者: Jukka Westerbacka.;Anna Kotronen.;Barbara A Fielding.;John Wahren.;Leanne Hodson.;Julia Perttilä.;Tuulikki Seppänen-Laakso.;Tapani Suortti.;Johanna Arola.;Rolf Hultcrantz.;Sandra Castillo.;Vesa M Olkkonen.;Keith N Frayn.;Matej Orešič.;Hannele Yki-Järvinen.
来源: Gastroenterology. 2010年139卷6期1961-1971.e1页
Animal studies suggest that endocannabinoids could contribute to the development of nonalcoholic fatty liver disease (NAFLD). In addition, NAFLD has been shown to be associated with multiple changes in lipid concentrations in liver biopsies. There are no data on splanchnic free fatty acid (FFA), glycerol, ketone body, endocannabinoid, and lipid fluxes in vivo in subjects with NAFLD.
737. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
作者: Stefan Zeuzem.;Mark S Sulkowski.;Eric J Lawitz.;Vinod K Rustgi.;Maribel Rodriguez-Torres.;Bruce R Bacon.;Mircea Grigorescu.;Alan D Tice.;Yoav Lurie.;Janusz Cianciara.;Andrew J Muir.;Patrick W Cronin.;Erik Pulkstenis.;G Mani Subramanian.;John G McHutchison.; .
来源: Gastroenterology. 2010年139卷4期1257-66页
The current standard of care for patients with chronic hepatitis C virus (HCV) genotype 1 is once-weekly pegylated interferon-α (Peg-IFNα) plus daily ribavirin for 48 weeks. We evaluated the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of albumin and IFNα-2b.
738. Acupuncture for irritable bowel syndrome: a protocol for a pragmatic randomised controlled trial.
作者: Hugh MacPherson.;Martin Bland.;Karen Bloor.;Helen Cox.;David Geddes.;Arthur Kang'ombe.;Julie Reynolds.;Eugena Stamuli.;Tracey Stuardi.;Helen Tilbrook.;David Torgerson.;Peter Whorwell.
来源: BMC Gastroenterol. 2010年10卷63页
There is insufficient evidence on the effectiveness of acupuncture for irritable bowel syndrome (IBS) for conclusions to be drawn. Given the current interest in acupuncture by patients, it is in the public interest to establish more rigorous evidence. Building on the positive findings from a pilot study, in this paper we present the protocol for a fully-powered trial designed to establish whether or not acupuncture is effective and cost-effective.
739. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension.
作者: Shiv Kumar Sarin.;Nitin Gupta.;Sanjeev Kumar Jha.;Amit Agrawal.;Smruti Ranjan Mishra.;Barjesh Chander Sharma.;Ashish Kumar.
来源: Gastroenterology. 2010年139卷4期1238-45页
Variceal bleeding increases morbidity and mortality among patients with noncirrhotic portal hypertension (NCPH). Blockers of β-adrenergic receptor signaling and endoscopic variceal ligation (EVL) have been used to prevent recurrence of bleeding, based on data from cirrhotic patients. We compared the efficacy and safety of the β-blocker propranolol with that of EVL in preventing the recurrence of variceal bleeding in patients with NCPH.
740. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
作者: Patricia A Thompson.;Betsy C Wertheim.;Jason A Zell.;Wen-Pin Chen.;Christine E McLaren.;Bonnie J LaFleur.;Frank L Meyskens.;Eugene W Gerner.
来源: Gastroenterology. 2010年139卷3期797-805, 805.e1页
Combination of polyamine and prostaglandin E2 (PGE2)-synthesis inhibitors reduced the risk of colorectal adenoma (CRA) by 70% in patients who received polypectomies. We studied effects of the combination of difluoromethylornithine (DFMO) and sulindac on biomarkers and investigated factors that modify their efficacy.
|